Loading news...
Vertex Pharmaceuticals Incorporated (VRTX) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Vertex (VRTX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
111 Capital bought a new position in Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) in the undefined quarter, according to its most recent disclosure with the SEC. The firm bought 4,363 shares of the pharmaceutical company's stock, valued at approximately $1,709,000. Other large investors have also recently modified their holdings of the company. Vanguard Group
Shares of Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX - Get Free Report) have been assigned an average rating of "Moderate Buy" from the twenty-seven ratings firms that are presently covering the firm, Marketbeat reports. Five analysts have rated the stock with a hold recommendation and twenty-two have issued a buy recommendation on the company. The average 1
The article presents a rigorously screened list of 10 top closed-end funds, or CEFs, for income investors, offering an average 9.7% yield and -10% NAV discount. Selections emphasize sector diversification, long-term outperformance, sustainable distributions, and attractive valuations, with a focus on both equity and credit-oriented CEFs. CEFs are generally characterized by higher volatility and deeper drawdowns than the broader market. For these reasons, they are not suited for everyone.
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX - Get Free Report) EVP Duncan Mckechnie sold 4,910 shares of the business's stock in a transaction that occurred on Wednesday, February 25th. The shares were sold at an average price of $487.65, for a total value of $2,394,361.50. Following the transaction, the executive vice president directly owned 17,559 shares in
CVS Health is making changes that could improve its business this year. Vertex Pharmaceuticals should see strong commercial and clinical progress in 2026.
This company is the global leader in its specialty area and has successfully expanded into other areas, too. This player aims to generate $13 billion in sales this year.
Guru Stock PicksBernard Horn has made the following transactions:Reduce in XSWX: BARN by 39.89%Sold out in CGAdd in TSN by 18.45%New position in HKSE:01299Stock
Vertex Pharmaceuticals' market-beating returns over the past 10 years wouldn't have been enough to turn $100,000 into $1 million. Though it still has strong prospects, this goal seems far too difficult to achieve.
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX - Get Free Report) EVP Ourania Tatsis sold 1,500 shares of the stock in a transaction that occurred on Friday, February 13th. The shares were sold at an average price of $499.99, for a total transaction of $749,985.00. Following the sale, the executive vice president owned 46,132 shares in the company,
I believe Vertex Pharmaceuticals Incorporated's bull run has come to an end. There's a divergence between its stock price growth over the past 5 months and the performance of Journavx and the cystic fibrosis franchise. So, in Q4, Trikafta+Kaftrio sales declined 3.1% quarter-on-quarter to about $2.57 billion, missing my "base case" scenario by $45 million.
Grange Capital LLC acquired a new stake in Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 3,554 shares of the pharmaceutical company's stock, valued at approximately $1,392,000. Vertex Pharmaceuticals makes up 1.3% of Grange Capital LLC's
Vertex Pharmaceuticals is the leader in cystic fibrosis treatment. The company has also expanded into other areas in recent years, winning approval for two new drugs.
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in TD Cowen's 46th Annual Health Care Conference. Reshma Kewalramani, President and Chief Executive Officer will participate in a fireside chat on Tuesday, March 3, 2026, at 9:10 a.m. ET. A live webcast of management's remarks will be available through the Vertex website, www.vrtx.com, in the "Investors" section under the "News and Events" page. A replay of the conference webcast.
Vertex (VRTX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Vertex Q4 earnings miss estimates, but revenues top forecasts on strong CF sales and momentum from new launches like Alyftrek, Casgevy and Journavx.
Vertex Pharmaceuticals shares dipped 1.24% in after-hours trading Thursday despite reporting a 10% rise in fourth-quarter revenue to $3.19 billion.
Vertex Pharmaceuticals Incorporated (VRTX) Q4 2025 Earnings Call Transcript
Although the revenue and EPS for Vertex (VRTX) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.